Manage Your Liver
Q:

What is NAFLD & NASH?

A:

Nonalcoholic fatty liver disease (NAFLD) is the buildup of extra fat in liver cells that is not caused by alcohol. In most people, early forms of NAFLD are unlikely to cause harm. However, if the fat continues to build up, it can eventually lead to inflammation or fibrosis of the liver.

 

Nonalcoholic steatohepatitis (NASH) is the more severe form of NAFLD. NASH causes liver inflammation and damage by an accumulation of fat in the liver which is not related to alcohol. NAFLD & NASH tends to develop in people who are overweight or obese, or have diabetes, high cholesterol or high triglycerides.

 

Up to 25% of adults with NASH may have cirrhosis.

 

Most people with NASH are between 40 and 60 years old. It is more common in women than in men. NASH is one of the leading causes of cirrhosis in adults in the US.

 

Causes

Things that put people at risk for NAFLD and NASH:

  • Obesity
  • Diabetes
  • High cholesterol and triglycerides
  • Metabolic syndrom

 

Signs and Symptoms

  • Loss of appetite
  • Fatigue
  • Nausea and vomiting
  • Abdominal pain

 

Diagnosis

An ultrasound of the liver can suggest the presence of a fatty liver. Other imaging studies may be used as well such as a computed tomography (CT) scan, or magnetic resonance imaging (MRI). In some cases, your doctor may advise a liver biopsy, it will help determine the exact cause.

 

Treatment

Currently, there is no medication proven to effectively treat fatty liver disease, if the main causes are related to obesity, diabetes and dyslipidemia. The standard recommendations to fatty liver disease patients are to reach a healthy weight, avoid alcohol, follow a healthy diet and exercise regularly.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
“It isn't fat but rather fibrosis that drives disease progression in people with advanced non-alcoholic steatohepatitis (NASH).”   NASH is one of the most prevalent liver diseases nowadays. NASH is related to non-alcoholic fatty liver disease (NAFLD) which is characterized by the buildup of fat in the liver. Although it is normal to have some fat in the liver, some people might develop inflammation because of this fat accumulation, this is cal
A:
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common liver diseases. They occur in people who drink little or no alcohol at all and are considered to be consequences of obesity.    However, “not obese” does not equal “no NAFLD / NASH”, since NAFLD may not be linked with obesity in some cases. Fatty liver disease may also develop in non-obese people. The terms “lean NAFLD” and “lean
Hit Questions
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
YHK has significant effect in stopping liver inflammation; it can enhance the recovery of liver health and protect liver cells. Those who have experienced YHK often have these questions in mind: Why is YHK so different from other liver medicines and supplements? Why is it possible to have such unprecedented effects? The answer seems magical, but in fact, it is not complicated - Because YHK possesses a perfect balance.   To explain this, we must first point out that YH
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us